Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sangamo Therapeutics filings document regulatory, clinical, financial and corporate-status disclosures for a genomic medicine company developing gene therapy and genome-engineering technologies. Recent 8-K reports cover operating and financial results, clinical data from the STAAR study of isaralgagene civaparvovec, or ST-920, regulatory-pathway disclosures for Fabry disease, and material-event updates tied to the company's neurology pipeline.
The filing record also includes Nasdaq listing-compliance and delisting notices, SGMO common-stock registration information, finance leadership and officer-transition disclosures, and capital-structure information. These documents formalize the company's reported results, governance changes, securities status and clinical-regulatory events under SEC reporting rules.
Sangamo Therapeutics filed a Form S-8 to register an additional 14,000,000 shares of common stock to be issued pursuant to its Amended and Restated 2018 Equity Incentive Plan. The filing incorporates prior Form S-8 registrations for 19,131,725, 9,900,000, 7,900,000, 10,000,000 and 11,000,000 shares.
The submission relies on incorporation by reference to the company’s recent periodic reports and includes key exhibits such as the Amended Plan and legal opinions; corporate officers including the CEO and CFO signed the registration.
Sangamo Therapeutics (SGMO) reported positive topline data from its registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease. In 32 treated adults, a single infusion produced a mean annualized eGFR slope of +1.965 mL/min/1.73 m²/year at 52 weeks, contrasting with published slopes of -2.2 to -0.4 mL/min for current standard therapies. Among 19 patients with 104-week follow-up, the slope remained positive at +1.747 mL/min, the FDA-endorsed intermediate endpoint for Accelerated Approval.
Secondary outcomes were uniformly favorable. All 18 patients initially on enzyme-replacement therapy discontinued ERT and remained off treatment, while plasma lyso-Gb3, cardiac parameters and α-Gal A activity stayed stable or improved for up to 4.5 years. Patient-reported outcomes showed statistically significant gains across multiple SF-36 domains and reductions in gastrointestinal symptoms, pain-medication use and anhidrosis.
Safety profile appeared benign: most adverse events were grade 1-2; no pre-conditioning, no safety-related discontinuations. The most common TEAEs were pyrexia (60.6%), COVID-19 (36.4%), headache (33.3%) and nasopharyngitis (33.3%).
The dataset supports SGMO’s plan to file a BLA under the Accelerated Approval pathway as early as Q1 2026. ST-920 already holds Orphan Drug, Fast Track and RMAT designations, plus EU and UK incentives. Full analyses will be presented at a future conference, and management is pursuing a commercialization partnership.